Session Registration form 4
Event Timing: February 4, 2019
Event Address: EPHI auditorium
Contact us at : ESOG , Ras Desta Damtew Avenue
Tsehafi Tízaz Teferawork Keda Bldg (Near Ghion Hotel)
East Wing, 2nd Floor, Room no 7

Tel: 251-11-5506068/69

Email address *
Open for everyone interested
SESSION 1: Presentation on different topics with various professionals
Morning Session
Venue: EPHI Auditorium
Moderators: Dr. Abdulfetah Abdulkadir and Dr. Munir Kassa
1. Ethical opinions in OBGYN 8:30-9:15 by Peter Schwartz and colleagues
Moderator: Dr. Munir Kassa
Learning objectives:
 be able to solve maternal-fetal conflicts
 understand adolescent decision making in reproductive health
 Identify components of informed consent.
2. Cardiologist's approach to Risk Assessment of cardiac disease in pregnancy 9:15-10:00
By Dr. Dejuma Yadeta
Learning objectives:
 Identify which pregnancies are associated with high cardiovascular risk
 choose risk assessment models most appropriate for their patients
 Identify cardiac lesions in which pregnancy is contraindicated
3. The pregnant cardiac patients: Cardiac catastrophes 10:15 - 10:45 by Dr. Thut Teshome
Learning objectives:
 What are the riskiest cardiac conditions for anesthesia in pregnancy?
 What are the essential steps to optimize anesthetic care?
 How to manage cardiac catastrophe in labour and delivery?

4. Congenital Heart Disease (Cyanotic Vs. Non-cyanotic) in pregnancy 10:45-11:15 by Dr. Esubalew Woldeyes
Learning objectives:
 Describe common congenital defects in pregnancy
 Discuss unique challenges of the Eeisenmenger Syndrome patient
 Review management approach
5. Valvular disease of the heart in pregnancy 11:15 - 11:45 by Dr. J. Igor Iruretagoyena
Learning objectives:
 How does valve disease present in pregnancy?
 What kind of valve disease caries the highest Vs. lowest maternal risk
 How to best manage valve disease in pregnancy

Discussion 11:45 - 12:00


Afternoon 13:00 - 15:30
Moderators: Dr. Wondimu Gudu and Dr. Eyasu Mesfin
6. Controversies in anticoagulation in pregnancy 13:00 - 13:30 by Dr. J. Igor Iruretagoyena
Learning Objectives:
 Understand valvular heart disease guideline emphasizing on anti-coagulation
 Describe fetotoxicity of Warfarin anticoagulation
 Understand optimal management protocol during pregnancy
7. Recent Progress in Inflammation Associated Preterm Birth and Neonatal Sepsis 13:30 - 14:00 by Professor Catalin Buhimschi
 Become familiar with the concept of amniotic fluid biomarkers of inflammation/infection
 Outline the discovery process of cord blood biomarkers of neonatal sepsis
 Outline clinical management options
8. Preeclampsia: research update, challenges and new opportunities 14:00 - 14:30 by Professor Irina Buhimschi
Learning objectives:
 Review pathogenic pathways leading to preeclampsia/eclampsia
 Review the clinical classifications of hypertensive disorders of pregnancy and the implications of recent changes for different health care settings
 Introduce the notions of protein misfolding and proteostasis with relevance to preeclampsia and to other human diseases
 Summarize results of recent clinical studies aimed at improving diagnosis of preeclampsia to reduce severe morbidity and mortality
9. Management of Rh-alloimmunisation by Dr. Delayehu Bekele 14:30-15:00
Learning objectives:
 Be able to explain the evolving role of cfDNA in determining which patient should
receive antenatal Rhesus immune globulin
 Understand proper reporting and use of MCA Doppler and
 Understand the management of the alloimmunized pregnancy
10. Updates on the Management of contraception in women with medical conditions 15:00-15:30 by Dr. Sarah W. Prager
Learning objectives:
 Discuss current epidemiology of medical conditions among women who require contraception.
 Discuss effects of contraceptives on medical conditions and vice-versa.
 Update contraceptive options for women with medical conditions
11. Update on approach to evaluation and management of female factor infertility 15:30- 16:00 by Dr. Parul Katiyar
Learning objectives:
 Describe the current status and role of female factor infertility including epidemiology and etiologies.
 Discuss evaluation plan/algorism of female factor infertility.
 Discuss the medical and surgical management approaches to female factor infertility including their indications, outcome and limitations.
Discussion: 16:00 - 16:15
Tea and Coffee 16:15-16:30

Full Name *
Your answer
Telephone *
Your answer
Organization *
Your answer
A copy of your responses will be emailed to the address you provided.
Submit
Never submit passwords through Google Forms.
reCAPTCHA
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service